艾曲泊帕联合CsA及G-CSF治疗重型再生障碍性贫血的回顾性研究  

A retrospective study of Eltrombopag combined with CsA and G-CSF in the treatment of severe aplastic anemia

作　　者：王超 Wang Chao(Department I of Hematology,the First Affiliated Hospital of Nanyang Medical College,Nanyang 473000,China)

机构地区：[1]南阳医学高等专科学校第一附属医院血液内科一病区,河南南阳473000

出　　处：《临床医学》2021年第12期91-93,共3页Clinical Medicine

摘　　要：目的研究艾曲泊帕联合环孢素A(CsA)、粒细胞集落刺激因子(G-CSF)治疗重型再生障碍性贫血的效果。方法选择2017年1月至2020年1月重型再生障碍性贫血患者72例,采用随机数表法分成治疗组和对照组,每组36例。两组均使用艾曲泊帕治疗,治疗组患者联合使用CsA和G-CSF,比较两组患者治疗效果和不良反应发生情况。结果治疗组总体反应率(88.9%,32/36)比对照组(66.7%,24/36)高,不良反应发生率少于对照组,差异有统计学意义(P<0.05)。结论联合使用艾曲泊帕、CsA和G-CSF治疗重型再生障碍性贫血,疗效显著,安全可靠。Objective To study the effect of Eltrombopag combined with CsA and G-CSF on severe aplastic anemia.Methods Seventy-two patients with severe aplastic anemia from January 2017 to January 2020 were randomly divided into treatment group and control group,with 36 cases in each group.Both groups were treated with Eltrombopag,and the patients in the treatment group were treated with CsA and G-CSF besides Eltrombopag.The therapeutic effects and adverse reactions of the two groups were compared.Results The overall response rate of the treatment group(88.9%,32/36)was significantly higher than that of the control group(66.7%,24/36),and the incidence of adverse effects was significantly lower than that of the control group,the differences between the groups were significant(P<0.05).Conclusions The combined use of Eltrombopag,CsA and G-CSF in the treatment of severe aplastic anemia has significant efficacy and high safety.

关 键 词：重型再生障碍性贫血 艾曲泊帕 粒细胞集落刺激因子 免疫抑制治疗 环孢素A 

分 类 号：R556.5[医药卫生—血液循环系统疾病]